The Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in a Complete Response Letter (CRL) for etripamil nasal spray (Cardamyst ™ ), an investigational ...

FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support ...

A new study shows that oxytocin nasal spray helps mothers with postpartum depression interact more positively with their babies.

Today’s health headlines: ketamine nasal sprays offer a new option for people with treatment-resistant depression. Plus, how ...

A panelist discusses how recent insights into dry eye disease highlight the importance of targeting both inflammation and tear production—showcasing treatments like cyclosporine drops and varenicline ...

Milestone Pharmaceuticals (MIST) stock falls amid a capital raise as FDA agrees to review its resubmitted NDA for heart therapy Cardamyst. Read more here.

Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the ...

People with hay fever could one day benefit from a first-of-its-kind “molecular shield” that blocks pollen from entering the ...

Vaccine experts have developed an antibody that, when applied to the nose, intercepts allergens before they can trigger a ...

ARS Pharmaceuticals' Neffy, an epinephrine nasal spray, is poised as a game-changer for emergency allergies, driving growth.

Evoke Pharma's stock soared 168% on Wednesday after the company announced it had received a new U.S. patent that could extend ...